Intravenous Vitamin C Administration Improved Blood Cell Counts and Health-Related Quality of Life of Patient with History of Relapsed Acute Myeloid Leukaemia

Antioxidants
Mike N FosterMike G Fitzpatrick

Abstract

A 52-year-old female presented to Integrated Health Options Clinic in October 2014 with a history of relapsed acute myeloid leukaemia (AML, diagnosed in 2009 and relapsed in 2014). Intravenous(IV) vitamin C therapy was initiated (in 2014) following completion of chemotherapy as an alternative to haematopoietic stem cell transplantation. IV vitamin C was administered twice weekly at a dose of 70 g/infusion. Within 4 weeks of initiation of IV vitamin C therapy, there was a dramatic improvement in the patient's blood indices with platelet cell counts increasing from 25 × 10⁸/L to 196 × 10⁸/L and white blood cell counts increasing from 0.29 × 10⁸/L to 4.0 × 10⁸/L, with further improvements observed over the next 18 months. Furthermore, there was a clear and sustained improvement in the patient's health-related quality of life scores assessed using a validated questionnaire. She has remained healthy and in complete remission until the present day. This case study highlights the benefits of IV vitamin C as a supportive therapy for previously relapsed AML.

References

Jul 20, 2002·Lancet·John A Liu Yin, David Grimwade
Apr 8, 2004·Annals of Internal Medicine·Sebastian J PadayattyMark Levine
Sep 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·Qi ChenMark Levine
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Dec 17, 2009·The British Journal of Nutrition·Jens Lykkesfeldt, Henrik E Poulsen
Aug 1, 2002·Current Protocols in Toxicology·Jens Lykkesfeldt
Apr 30, 2013·Antioxidants & Redox Signaling·Nermi L ParrowMark Levine
Dec 18, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yasuhito NannyaMineo Kurokawa
Oct 4, 2014·Free Radical Biology & Medicine·Caroline KuiperKevin O Hicks
Mar 26, 2016·Results in Immunology·Mirelle J A J HuijskensGerard M J Bos
Aug 31, 2016·Proceedings of the National Academy of Sciences of the United States of America·Minmin LiuPeter A Jones
Aug 22, 2017·Nature·Michalis AgathocleousSean J Morrison
Sep 29, 2017·Blood Cells, Molecules & Diseases·Domenico MastrangeloUgo Testa

❮ Previous
Next ❯

Citations

Oct 12, 2018·Biochemical Society Transactions·Abel AngMargreet C M Vissers
Dec 24, 2020·Nutrients·Kinga LinowieckaAnna A Brożyna

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.